An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03739970` - A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function	N/A
Completed	`NCT01941446` - A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization	Phase 1
Completed	`NCT05447546` - Study to Evaluate HT-6184 in Healthy Subjects	Phase 1
Completed	`NCT03677921` - A Clinical Trial of Bio-Germanium for the Evaluation of Efficacy on Immune Function	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT03739970 - A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function

N/A

Completed

NCT01941446 - A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Phase 1

Completed

NCT05447546 - Study to Evaluate HT-6184 in Healthy Subjects

Phase 1

Completed

NCT03677921 - A Clinical Trial of Bio-Germanium for the Evaluation of Efficacy on Immune Function

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01652859
Study type	Interventional
Source	Taiwan Liposome Company
Contact
Status	Completed
Phase	Phase 1
Start date	February 2012
Completion date	December 2012

An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms